Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?
Rattachement africain : nl, gb, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: The correlation between plasma and saliva concentration of anti-seizure medication (ASM) is well established, but variability limits the acceptance of saliva-based Therapeutic Drug Monitoring (TDM). We analysed the correlation between salivary levetiracetam and lamotrigine levels, and efficacy and tolerability. METHODS: Blood and saliva samples were collected over two years. Seizure freedom was defined as three times the longest pre-treatment inter-seizure interval or at least one year seizure-free without treatment changes. Adverse effects were assessed during visits. Lamotrigine and levetiracetam saliva and plasma concentrations were compared across groups based on treatment response and adverse effects. Response and adverse events predictors were analysed using binary logistic regression. RESULTS: Among 296 adults with epilepsy, 84 (28 %) achieved seizure freedom. These patients were older, predominantly on monotherapy, and underwent fewer ASM trials. 27 patients (9 %) reported adverse effects and were older at epilepsy onset. Seizure-free lamotrigine users had a lower dosage (median 2 vs 3.3 mg/kg, p = 0.07), and lower plasma and salivary concentrations (median plasma 2.6 vs 3.9 mg/L, p = 0.026; median saliva 1.4 vs 2.4 mg/L, p = 0.011). No association was found between lamotrigine dosage, levels, and adverse events. Levetiracetam users reporting side effects had higher salivary concentrations (median 20 vs 14.40 mg/L, p = 0.04), while seizure-free individuals showed no difference in salivary levels, although dosages and plasma levels differed. CONCLUSION: This study highlights the clinical relevance of saliva TDM, linking salivary drug levels to treatment response for lamotrigine and adverse effects for levetiracetam. Salivary ASMs levels may complement plasma TDM, enhancing individualised treatment.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?
- Date Crossref
- 01/10/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Stichting Epilepsie Instellingen Nederland pays non établi dans la noticeÉtablissement de santé
-
UCL Queen Square Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
Centre Hospitalier Universitaire Vaudois pays non établi dans la noticeÉtablissement de santé
-
Hôpital Orthopédique de la Suisse Romande pays non établi dans la noticeÉtablissement de santé
-
University Hospital (CHUV) and Faculty of Biology and Medicine of Lausanne Department of Clinical Neurosciences pays non établi dans la noticeUniversité ou école supérieure
Stichting Epilepsie Instellingen Nederland, UCL Queen Square Institute of Neurology et University College London, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.